TRR 77

Liver Cancer - From Molecular Pathogenesis to Targeted Therapies

Hepatocellular carcinoma (HCC) is one of the most frequent and dismal malignancies with so far limited therapeutic options but also an ideal model system for tumour research and the most relevant paradigm for virus-induced and inflammation-mediated cancer. Recent progress has demonstrated the feasibility of translating basic biomedical research findings into HCC therapy. The main aim of the SFB/TRR77 is to gain a profound understanding of the molecular basis of human hepatocarcinogenesis beginning with its initiation from chronic liver disease to its progression into metastatic cancer, its functional dissection and the identification of novel preventive, diagnostic, and therapeutic approaches.

Partners

Hannover Medical School

Heidelberg University Hospital

Speaker

Professor Dr. Peter Schirmacher (Universitätsklinikum Heidelberg)

Homepage

www.livercancer.de

Funding Agency

DFG - German Research Foundation